Cargando…
Live attenuated vaccines in patients receiving immunosuppressive agents
The use of live attenuated vaccines in patients with immunosuppressive agents is contraindicated in package inserts and guidelines in Japan and other countries. However, patients receiving immunosuppressants have a high risk of infectious disease becoming severe, and the necessity to prevent infecti...
Autor principal: | Kamei, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115603/ https://www.ncbi.nlm.nih.gov/pubmed/37076756 http://dx.doi.org/10.1007/s00467-023-05969-z |
Ejemplares similares
-
Prospective study of live attenuated vaccines for patients receiving immunosuppressive agents
por: Kamei, Koichi, et al.
Publicado: (2020) -
Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents
por: Kamei, Koichi, et al.
Publicado: (2022) -
Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery
por: Lin, Ivan Y. C., et al.
Publicado: (2015) -
Maternal outcomes among pregnant women receiving live attenuated influenza vaccine
por: Toback, Seth L., et al.
Publicado: (2011) -
Blood B Cell Depletion Reflects Immunosuppression Induced by Live-Attenuated Infectious Bursal Disease Vaccines
por: Courtillon, Céline, et al.
Publicado: (2022)